news
FDA grants Orphan Drug Designation to DYN101 treatment
A treatment for Centronuclear Myopathies has received Orphan Drug Designation from the FDA and will begin Phase I/II trials.
List view / Grid view
Orphan Drugs
Filter the results
news
FDA grants Orphan Drug Designation for narcolepsy treatment
The FDA has given the XWL-008 compound Orphan Drug Designation for the treatment of narcolepsy.
news
FDA approves first gene therapy for paediatric spinal muscular atrophy
The FDA has given approval to AveXis for the first treatment of paediatric spinal muscular atrophy (SMA).
product
Eurofins Amatsigroup ǀ Your cDmo partner
Frédéric Gaussens from Eurofins Amatsigroup (CDMO) giving an overview of the services they provide...
news
FDA grants orphan drug designation to elamipretide for LHON
The FDA granted Orphan Drug Designation to elamipretide, for the treatment of Leber's hereditary optic neuropathy...
news
FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia
The FDA has approved Crysvita, the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia, a rare, inherited form of rickets...
news
KL1333 receives FDA ODD for mitochondrial diseases
NeuroVive Pharmaceutical AB has been granted Orphan Drug Designation for its project KL1333 for treatment of inherited mitochondrial respiratory chain diseases...
news
FDA expands approval of Blincyto for treatment of B-cell precursor ALL
The FDA has granted accelerated approval to Blincyto to treat adults and children with B-cell precursor acute lymphoblastic leukaemia (ALL)...
news
FDA approves Lutathera for somatostatin receptor-positive GEP-NETs
The FDA has approved Lutathera for the treatment of a type of cancer that affects the pancreas the gastrointestinal tract...
news
Enzyme replacement therapy to treat alpha-mannosidosis
The EMA has recommended granting a marketing authorisation in the EU for Lamzede a long-term enzyme replacement therapy for alpha-mannosidosis...
news
EC grants orphan drug designation for Gilteritinib for the treatment of AML
The European Commission has issued Orphan Designation to gilteritinib for the treatment of patients with acute myeloid leukaemia...
news
FDA accepts IND for the treatment of mucopolysaccharidosis type IIIA
The FDA has issued a Study may proceed letter for the first study in humans, thereby accepting the investigational new drug application for the drug candidate SOBI003...
news
FDA approves Nucala for Eosinophilic Granulomatosis with Polyangiitis
The FDA has expanded the approved use of Nucala to treat a rare autoimmune disease that causes vasculitis, an inflammation of the wall of blood vessels of the body...
news
EMA grants marketing authorisation for Prevymis against cytomegalovirus
10 November 2017 | By
The EMA has recommended granting a marketing authorisation Prevymis, an antiviral medicine that prevents CMV reactivation and disease...
news
FDA approves Zelboraf for certain patients with Erdheim-Chester disease
The FDA has expanded the approval of Zelboraf to include the treatment of certain adult patients with Erdheim-Chester Disease, a rare cancer of the blood...